This hypothesis is consistent with numerous reports linking tumour cell ErbB2 overexpression and p53 dysfunction (Horak et al, 1991; Mehta et al, 1995; Li et al, 1997) and identifying poor-prognosis clinical subgroups based on concurrence of these phenotypes (Tsuda et al, 1998). This evidence concerns the gene ERBB2 and neoplasm.